David A. Siegel Fate Therapeutics Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 927,240 shares of FATE stock, worth $2.06 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

927,240

Previous 1,523,500 39.14%

Holding current value

$2.06 Million

Previous $5 Million 35.06%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $1.86 Million - $3.32 Million	-596,260 Reduced 39.14%	927,240 $3.25 Million
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $279,708 - $607,464	85,800 Added 5.97%	1,523,500 $5 Million
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $1.55 Million - $3.67 Million	-439,200 Reduced 23.4%	1,437,700 $10.6 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $92,235 - $220,246	-55,900 Reduced 2.89%	1,876,900 $7.02 Million
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $233,310 - $582,120	115,500 Added 6.36%	1,932,800 $4.1 Million
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $254,660 - $352,565	-53,500 Reduced 2.86%	1,817,300 $8.65 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $5.06 Million - $13.3 Million	1,192,400 Added 175.77%	1,870,800 $10.7 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $6.21 Million - $15 Million	629,400 Added 1284.49%	678,400 $6.85 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $21,040 - $36,060	1,000 Added 2.08%	49,000 $1.1 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $471,170 - $1.12 Million	-26,500 Reduced 35.57%	48,000 $1.19 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $5.28 Million - $10.7 Million	-178,100 Reduced 70.51%	74,500 $2.89 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $9.25 Million - $12.4 Million	-193,400 Reduced 43.36%	252,600 $14.8 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $17 Million - $27.4 Million	-286,000 Reduced 39.07%	446,000 $26.4 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $6.18 Million - $8.5 Million	-91,900 Reduced 11.15%	732,000 $63.5 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $16.3 Million - $26.5 Million	225,631 Added 37.71%	823,900 $67.9 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $8.58 Million - $22.7 Million	225,169 Added 60.35%	598,269 $54.4 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $6.64 Million - $8.85 Million	218,500 Added 141.33%	373,100 $14.9 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $1.65 Million - $2.87 Million	81,600 Added 111.78%	154,600 $5.3 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $1.44 Million - $2.65 Million	-83,200 Reduced 53.27%	73,000 $1.62 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $713,687 - $1.1 Million	-53,300 Reduced 25.44%	156,200 $3.06 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $745,654 - $1.08 Million	-48,200 Reduced 18.7%	209,500 $3.25 Million
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $1.22 Million - $1.6 Million	-78,400 Reduced 23.33%	257,700 $5.23 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $270,890 - $385,426	-20,600 Reduced 5.78%	336,100 $5.91 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $777,196 - $1.15 Million	67,700 Added 23.43%	356,700 $4.58 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $769,125 - $1.43 Million	87,900 Added 43.71%	289,000 $4.71 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $260,144 - $382,832	28,400 Added 16.44%	201,100 $2.28 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $638,190 - $1.39 Million	101,300 Added 141.88%	172,700 $1.69 Million
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $202,516 - $341,296	51,400 Added 257.0%	71,400 $436,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $52,000 - $86,199	20,000	20,000 $79,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account